Teriflunomide in SCMC vs. Sweetened Milk in SJL/J Mice
In a study involving female SJL/J mice, teriflunomide (TF) delivered with sucrose-containing carboxymethylcellulose (SCMC) was shown to reduce the severity of experimental autoimmune encephalomyelitis (EAE) and delay disease onset compared to vehicle controls. In contrast, teriflunomide in sweetened milk (SM) did not produce sustained therapeutic benefits. The study also noted a significant difference in TF distribution between the two delivery methods.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not yet tested in people
- Mechanism
- Not reported
- Evidence strength
- Early – laboratory or animal research
- Outcome
- Not reported
Results in cells or animals often do not carry over to people with MS.
Why it matters
Understanding how drug delivery vehicles impact the efficacy of treatments like teriflunomide is crucial for developing effective therapeutic strategies for multiple sclerosis. These findings may help refine how medications are delivered to maximize their benefits.
What this does not prove
Results are confined to an animal model and may not directly correlate with human multiple sclerosis treatment outcomes. Therefore, caution is needed when extrapolating these findings to human subjects.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-09-27
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- dihydroorotate dehydrogenase (DHODH)
- Pathway
- Not reported
- Population
- Twenty-four female SJL/J mice
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidenceDrug Delivery Vehicle-Teriflunomide Interactions Affect Treatment and Fluorine Magnetic Resonance in an Animal Model of Multiple Sclerosis. ↗DOI: 10.3390/pharmaceutics18101225
Supporting passages (11)
subjectsAnimal
publication date2026-09-27
interventionWe investigated whether sweetened milk (SM), compared with sucrose-containing carboxymethylcellulose (SCMC), affects the therapeutic efficacy, tissue distribution, and 19F MR signal of TF in experimental autoimmune encephalomyelitis (EAE), a mouse model of MS.
comparatorvehicle controls
primary endpointEAE severity
findingsTF in SCMC reduced EAE severity during peak disease and delayed disease onset, whereas TF in SM produced no sustained therapeutic benefit. Hepatic 19F MR signals were approximately twofold higher with SCMC than with SM, and brain TF concentrations were 4.8-fold higher.
biological targetsdihydroorotate dehydrogenase (DHODH)
populationTwenty-four female SJL/J mice
limitationsTitle: Drug Delivery Vehicle-Teriflunomide Interactions Affect Treatment and Fluorine Magnetic Resonance in an Animal Model of Multiple Sclerosis.
peer reviewedPublication types: Journal Article
human efficacyAnimal
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.